158 related articles for article (PubMed ID: 30833639)
1. HER2 and p95HER2 differentially regulate miRNA expression in MCF-7 breast cancer cells and downregulate MYB proteins through miR-221/222 and miR-503.
Gorbatenko A; Søkilde R; Sorensen EE; Newie I; Persson H; Morancho B; Arribas J; Litman T; Rovira C; Pedersen SF
Sci Rep; 2019 Mar; 9(1):3352. PubMed ID: 30833639
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic p95HER2 regulates Na+-HCO3- cotransporter NBCn1 mRNA stability in breast cancer cells via 3'UTR-dependent processes.
Gorbatenko A; Olesen CW; Loebl N; Sigurdsson HH; Bianchi C; Pedraz-Cuesta E; Christiansen J; Pedersen SF
Biochem J; 2016 Nov; 473(21):4027-4044. PubMed ID: 27609814
[TBL] [Abstract][Full Text] [Related]
3. Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer.
Li X; Xu Y; Ding Y; Li C; Zhao H; Wang J; Meng S
Mol Cancer; 2018 Aug; 17(1):113. PubMed ID: 30068375
[TBL] [Abstract][Full Text] [Related]
4. miR-200 affects tamoxifen resistance in breast cancer cells through regulation of MYB.
Gao Y; Zhang W; Liu C; Li G
Sci Rep; 2019 Dec; 9(1):18844. PubMed ID: 31827114
[TBL] [Abstract][Full Text] [Related]
5. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.
Scaltriti M; Rojo F; Ocaña A; Anido J; Guzman M; Cortes J; Di Cosimo S; Matias-Guiu X; Ramon y Cajal S; Arribas J; Baselga J
J Natl Cancer Inst; 2007 Apr; 99(8):628-38. PubMed ID: 17440164
[TBL] [Abstract][Full Text] [Related]
6. MYB controls erythroid versus megakaryocyte lineage fate decision through the miR-486-3p-mediated downregulation of MAF.
Bianchi E; Bulgarelli J; Ruberti S; Rontauroli S; Sacchi G; Norfo R; Pennucci V; Zini R; Salati S; Prudente Z; Ferrari S; Manfredini R
Cell Death Differ; 2015 Dec; 22(12):1906-21. PubMed ID: 25857263
[TBL] [Abstract][Full Text] [Related]
7. TGFβ-induced c-Myb affects the expression of EMT-associated genes and promotes invasion of ER+ breast cancer cells.
Cesi V; Casciati A; Sesti F; Tanno B; Calabretta B; Raschellà G
Cell Cycle; 2011 Dec; 10(23):4149-61. PubMed ID: 22101269
[TBL] [Abstract][Full Text] [Related]
8. miR-142-3p as tumor suppressor miRNA in the regulation of tumorigenicity, invasion and migration of human breast cancer by targeting Bach-1 expression.
Mansoori B; Mohammadi A; Ghasabi M; Shirjang S; Dehghan R; Montazeri V; Holmskov U; Kazemi T; Duijf P; Gjerstorff M; Baradaran B
J Cell Physiol; 2019 Jun; 234(6):9816-9825. PubMed ID: 30480817
[TBL] [Abstract][Full Text] [Related]
9. A novel double-negative feedback loop between miR-489 and the HER2-SHP2-MAPK signaling axis regulates breast cancer cell proliferation and tumor growth.
Patel Y; Shah N; Lee JS; Markoutsa E; Jie C; Liu S; Botbyl R; Reisman D; Xu P; Chen H
Oncotarget; 2016 Apr; 7(14):18295-308. PubMed ID: 26918448
[TBL] [Abstract][Full Text] [Related]
10. High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance).
Chumsri S; Sperinde J; Liu H; Gligorov J; Spano JP; Antoine M; Moreno Aspitia A; Tan W; Winslow J; Petropoulos CJ; Chenna A; Bates M; Weidler JM; Huang W; Dueck A; Perez EA
Clin Cancer Res; 2018 Jul; 24(13):3053-3058. PubMed ID: 29530935
[No Abstract] [Full Text] [Related]
11. The role of p95HER2 in trastuzumab resistance in breast cancer.
Ozkavruk Eliyatkin N; Aktas S; Ozgur H; Ercetin P; Kupelioglu A
J BUON; 2016; 21(2):382-9. PubMed ID: 27273948
[TBL] [Abstract][Full Text] [Related]
12. microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb.
Zhang J; Luo N; Luo Y; Peng Z; Zhang T; Li S
Int J Oncol; 2012 Mar; 40(3):747-56. PubMed ID: 22025269
[TBL] [Abstract][Full Text] [Related]
13. miR-448 inhibits the epithelial-mesenchymal transition in breast cancer cells by directly targeting the E-cadherin repressor ZEB1/2.
Ma P; Ni K; Ke J; Zhang W; Feng Y; Mao Q
Exp Biol Med (Maywood); 2018 Mar; 243(5):473-480. PubMed ID: 29368542
[TBL] [Abstract][Full Text] [Related]
14. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients.
Sperinde J; Jin X; Banerjee J; Penuel E; Saha A; Diedrich G; Huang W; Leitzel K; Weidler J; Ali SM; Fuchs EM; Singer CF; Köstler WJ; Bates M; Parry G; Winslow J; Lipton A
Clin Cancer Res; 2010 Aug; 16(16):4226-35. PubMed ID: 20664024
[TBL] [Abstract][Full Text] [Related]
15. Estrogen receptor beta as epigenetic mediator of miR-10b and miR-145 in mammary cancer.
Piperigkou Z; Franchi M; Götte M; Karamanos NK
Matrix Biol; 2017 Dec; 64():94-111. PubMed ID: 28797712
[TBL] [Abstract][Full Text] [Related]
16. Theranostic application of
Cava C; Novello C; Martelli C; Lodico A; Ottobrini L; Piccotti F; Truffi M; Corsi F; Bertoli G; Castiglioni I
Theranostics; 2020; 10(1):50-61. PubMed ID: 31903105
[TBL] [Abstract][Full Text] [Related]
17. Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer.
Lyu H; Wang S; Huang J; Wang B; He Z; Liu B
Cancer Lett; 2018 Apr; 420():97-108. PubMed ID: 29409974
[TBL] [Abstract][Full Text] [Related]
18. COX-2 Elevates Oncogenic miR-526b in Breast Cancer by EP4 Activation.
Majumder M; Landman E; Liu L; Hess D; Lala PK
Mol Cancer Res; 2015 Jun; 13(6):1022-33. PubMed ID: 25733698
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the miRNA-mRNA-lncRNA networks in ER+ and ER- breast cancer cell lines.
Wu Q; Guo L; Jiang F; Li L; Li Z; Chen F
J Cell Mol Med; 2015 Dec; 19(12):2874-87. PubMed ID: 26416600
[TBL] [Abstract][Full Text] [Related]
20. Lnc RNA SNHG20 participated in proliferation, invasion, and migration of breast cancer cells via miR-495.
Guan YX; Zhang MZ; Chen XZ; Zhang Q; Liu SZ; Zhang YL
J Cell Biochem; 2018 Nov; 119(10):7971-7981. PubMed ID: 29236315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
